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Inherited genetic variation of mitochondrial DNA (mtDNA) could account for the missing heritability of
human longevity and healthy aging. Here, we show no robust association between common genetic
variants of mtDNA and frailty (an “unhealthy aging” phenotype) or mortality in 700, more than 85-year-
old, participants of the Newcastle 85þ study. Conflicting data from different populations underscore our
conclusion that there is currently no compelling link between inherited mtDNA variants and aging.
 2013 The Authors. Published by Elsevier Inc. All rights reserved.1. Introduction
Human longevity shows heritability of w25%, but large-scale,
nuclear, genome-wide association studies have not yet clearly
established all the responsible genes (Beekman et al., 2013;
Kirkwood et al., 2011). In addition to nuclear genes, there may also
be contributions from the maternally inherited, extranuclear,
mitochondrial genome (mitochondrial DNA [mtDNA]). mtDNA
codes for 13 respiratory chain proteins that are essential for the
production of adenosine triphosphate, which is required for all
active intracellular processes. There is an emerging evidence that
mitochondrial dysfunction plays a key role in cellular aging, and the
accumulation of somatic mutations of mtDNA is associated with an
aging phenotype in mice and humans (Schon et al., 2012). It is,
therefore, of great interest that different polymorphic variants of
mtDNA appear to be enriched in cohorts of healthy older individ-
uals, raising the possibility that our mitochondrial genome may
influence how we age and how long we live. However, although
several studies support this hypothesis (Niemi et al., 2003, 2005;
Yang et al., 2012), there are conflicting findings and a lack ofer the terms of the Creative
ricted use, distribution, and
thor and source are credited.
for Mitochondrial Research,
Central Parkway, Newcastle
þ44 191 241 8666.
innery).
Published by Elsevier Inc. All righconsistency (Courtenay et al., 2012; De Benedictis et al., 1999; Feng
et al., 2011; Finnila et al., 2000; Ivanova et al., 1998; Ross et al., 2001;
Tanaka et al., 1998, 2000). Moreover, there have been no studies of
mtDNA and healthy aging phenotypes.
In an attempt to resolve these issues, we carried out a compre-
hensive study of mtDNA haplogroups in the Newcastle 85þ study.
Ten mtDNA haplogroup markers effectively tag the most common
subgroups of mtDNA found in 95% of the local population. The
Newcastle 85þ study provides a unique opportunity to study the
effects of these haplogroups both on survival up to and beyond age
85 and on frailty, an “unhealthy aging” phenotype, in a represen-
tative population-based cohort of the very old.
2. Experimental procedures
2.1. Study cohort
The Newcastle 85þ study has been reported and includes
a sociodemographically representative 1921 birth cohort recruited
at age w85 through general practice patient lists (n ¼ 845)
(Collerton et al., 2009). An assessment of frailty was performed at
baseline using 2 robust and validated measures: the Rockwood
frailty index (RFI) (Rockwood and Mitnitski, 2007) and the Fried
frailty status (FFS) (Fried et al., 2009), as described (Collerton et al.,
2012). RFI was available for 811 (96.0%) of the cohort and FFS for
552 (65.3%). The cohort has been followed for mortality from
baseline assessment (June 2006 to Sept 2007) until April 30, 2012.ts reserved.
Table 1
Comparison of haplogroup frequencies across cohorts, percent (n)
Mitochondrial
haplogroup
Newcastle
85þ study
age 85.5 y
(SD 0.4),
n ¼ 700
Local older
cohort age
68.9 y (SD 8.5),
n ¼ 93
1958 MRC
birth cohort,
n ¼ 2889
Local birth
cohort
neonates,
n ¼ 344
H 46.0 (322) 36.6 (34) 44.2 (1278) 39.8 (137)
V 3.6 (25) 3.2 (3) 3.0 (87) 3.5 (12)
J 11.0 (77) 8.6 (8) 11.6 (336) 9.9 (34)
T 10.3 (72) 3.2 (3) 10.0 (289) 13.1 (45)
U 15.4 (108) 15.1 (14) 12.9 (374) 15.1 (52)
K 7.3 (51) 7.5 (7) 9.3 (269) 7.8 (27)
Other (W, X, I, M
classified
here)
6.4 (45) 25.8 (24) 8.9 (256) 10.8 (37)
Key: SD, standard deviation; MRC, Medical Research Council.
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mtDNA haplogroups were determined using a stepwise algo-
rithm (Torroni et al., 1996) by primer extension of multiplex
polymerase chain reaction products with the detection of the allele-
specific extension products by matrix-associated laser desorption/
ionization time of flight (Sequenom MassARRAY, San Diego, CA,
USA). DNA was available for 752 participants; 52 cases were
excluded from the analysis because of either heteroplasmic status
(n ¼ 5) or inability to detect haplogroup/low-quality DNA (n ¼ 47),
leaving 700 with valid mitochondrial haplogroup data.
2.3. Statistical analysis
The frequency of mtDNA haplogroups in the incident Newcastle
85þ cohort (n ¼ 700) was compared with 3 ethnically matched
population control data sets representing different ages using
chi-squared analysis with pairwise comparisons of samples for
each haplogroup: (1) a local birth cohort (n ¼ 344, neonatal cord
blood samples), North Cumbria Community Genetics Project
(Elliott et al., 2008); (2) a national mid-age cohort, the 1958
Medical Research Council cohort (n ¼ 2889, 52% male), which has
previously been shown to be representative of control subjects
in our region (Chinnery et al., 2007); and (3) a local cohort ofTable 2
RFI and mitochondrial haplogroupdregression coefficients (unstandardized) for square r
Haplogroup Model 1, unstandardized regression
coefficient (95% confidence interval)
Model 1,
p value
Model 2
regressio
(95% con
H 0.015 (0.003 to 0.034) 0.101 0.017
Non-H Reference Referenc
T 0.006 (0.037 to 0.024) 0.684 0.009
Non-T Reference Referenc
J 0.016 (0.045 to 0.014) 0.300 0.014
Non-J Reference Referenc
U 0.009 (0.035 to 0.016) 0.481 0.009
Non-U Reference Referenc
K 0.033 (0.068 to 0.003) 0.069 0.033
Non-K Reference Referenc
X 0.060 (0.008 to 0.128) 0.083 0.057
Non-X Reference Referenc
W 0.015 (0.040 to 0.071) 0.585 0.012
Non-W Reference Referenc
I 0.052 (0.022 to 0.126) 0.170 0.047
Non-I Reference Referenc
V 0.019 (0.068 to 0.031) 0.461 0.020
Non-V Reference Referenc
Key: RFI, Rockwood frailty index.
a Linear regression models were fitted with RFI (square root transformed to give ad
independent variable. Seven binary variables were created of “in haplogroup H” versus
separately. Model 1 is unadjusted, model 2 adjusted for sex, and model 3 adjusted for sehealthy older subjects (n ¼ 93, 35% male; mean age 69, standard
deviation ¼ 8.5).
Mitochondrial haplogroup data were available for 85.8% (696/
811) of those with RFI available and 91.4% (477/552) of those with
FFS available. These were the samples used in the principal anal-
yses. Linear regression was used to determine the relationship
between mtDNA haplogroups and RFI, and ordinal logistic regres-
sion was used to determine the relationship between mtDNA
haplogroups and FFS, both before and after controlling for sex, years
of education, and smoking status. A count of chronic diseases was
used as an additional control for the FFS. The relationship between
mtDNA haplogroups and survival was determined by Cox propor-
tional hazards analysis, both before and after controlling for sex,
total cholesterol, body mass index, hypertension, diabetes,
ethnicity, and smoking status. The median follow-up period was 58
months during which 336 deaths occurred.
3. Results
The overall frequency distribution of mtDNA haplogroups in the
incident Newcastle 85þ cohort was compared with the birth cohort
(p ¼ 344), mid-age cohort (p ¼ 2889), and old-age cohort (p ¼ 93)
(Table 1). The only significant difference in distributions was for the
local older cohort that differed from each of the other cohorts in the
“other” haplogroup category only.
There was no significant association between mtDNA hap-
logroups and frailty (RFI or FFS) before and after controlling for the
potential confounding variables (Tables 2 and 3). Although we
observed an association between haplogroup X and increased
mortality (p¼0.025), thiswasnot apparent after controlling for total
cholesterol, body mass index, hypertension, diabetes, ethnicity, and
smoking status (Table 4). Likewise, the trend toward reduced
mortality associatedwithhaplogroupK (p¼ 0.041),which remained
after controlling for other variables (p ¼ 0.023), did not withstand
correction for the multiple haplogroups under investigation.
4. Discussion
We found no robust evidence of an association between mtDNA
haplogroups and either frailty or survival beyond age 85 or anyootetransformed RFI by mitochondrial haplogroupa
, unstandardized
n coefficient
fidence interval)
Model 2,
p value
Model 3, unstandardized
regression coefficient
(95% confidence interval)
Model 3,
p value
(0.001 to 0.036) 0.065 0.013 (0.006 to 0.031) 0.175
e Reference
(0.040 to 0.021) 0.536 0.007 (0.036 to 0.023) 0.663
e Reference
(0.043 to 0.015) 0.338 0.011 (0.040 to 0.018) 0.455
e Reference
(0.034 to 0.016) 0.488 0.008 (0.033 to 0.017) 0.526
e Reference
(0.068 to 0.002) 0.064 0.029 (0.064 to 0.007) 0.112
e Reference
(0.010 to 0.124) 0.098 0.053 (0.014 to 0.120) 0.122
e Reference
(0.043 to 0.066) 0.675 0.018 (0.037 to 0.072) 0.523
e Reference
(0.026 to 0.120) 0.206 0.051 (0.022 to 0.123) 0.169
e Reference
(0.069 to 0.029) 0.424 0.020 (0.069 to 0.028) 0.410
e Reference
equate model fit) as the dependent variable and mitochondrial haplogroup as the
“not in haplogroup H” type, and 7 models were run entering each binary variable
x, education, and smoking status.
Table 3
FFS and mitochondrial haplogroupdodds ratio (95% confidence interval) of being in a frailer Fried category (pre-frail versus robust or frail versus pre-frail) by mitochondrial
haplogroupa
Haplogroup Model 1, odds ratio
(95% confidence interval)
Model 1,
p value
Model 2, odds ratio
(95% confidence interval)
Model 2,
p value
Model 3, odds ratio
(95% confidence interval)
Model 3,
p value
H 1.05 (0.73e1.50) 0.790 1.10 (0.77e1.57) 0.608 1.04 (0.71e1.53) 0.832
Non-H Reference Reference Reference
T 1.10 (0.61e1.96) 0.752 0.93 (0.52e1.68) 0.815 0.80 (0.43e1.51) 0.498
Non-T Reference Reference Reference
J 0.72 (0.41e1.27) 0.262 0.74 (0.42e1.31) 0.305 0.99 (0.54e1.81) 0.968
Non-J Reference Reference Reference
U 0.95 (0.59e1.52) 0.816 0.95 (0.59e1.52) 0.820 0.85 (0.51e1.41) 0.526
Non-U Reference Reference Reference
K 0.66 (0.33e1.32) 0.248 0.70 (0.35e1.37) 0.293 0.79 (0.38e1.64) 0.532
Non-K Reference Reference Reference
X 4.45 (0.91e21.71) 0.065 4.32 (0.87e21.52) 0.074 3.64 (0.68e19.61) 0.132
Non-X Reference Reference Reference
W 2.58 (0.88e7.57) 0.084 2.30 (0.78e6.81) 0.131 2.90 (0.89e9.49) 0.078
Non-W Reference Reference Reference
I 0.95 (0.10e9.10) 0.967 0.89 (0.09e8.53) 0.918 1.14 (0.11e11.78) 0.913
Non-I Reference Reference Reference
V 1.20 (0.43e3.32) 0.729 1.29 (0.46e3.58) 0.630 1.20 (0.38e3.71) 0.757
Non-V Reference Reference Reference
Key: FFS, Fried frailty status.
a Ordinal logistic regression models were fitted with Fried status as the dependent variable and mitochondrial haplogroup as the independent variable. Seven binary
variables were created of “in haplogroup H” versus “not in haplogroup H” type, and 7models were run entering each binary variable separately. Model 1 is unadjusted, model 2
adjusted for sex only, and model 3 adjusted for sex, years of education, smoking status, and count of chronic diseases.
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overall distribution of mtDNA haplogroups closely resembled
ethnically matched cohorts from 3 different younger age groups.
Our findings do not support a role for mtDNA in promoting healthy
aging or longevity. The absence of an age-associated stratification of
mtDNA haplogroups is in agreement with previous findings in large
European cohorts (Benn et al., 2008; Dato et al., 2004). On the other
hand, our findings contrast with the results of several smaller
European (De Benedictis et al., 1999; Dominguez-Garrido et al.,
2009; Ivanova et al., 1998; Niemi et al., 2003; Ross et al., 2001)
and Far-Eastern studies (Feng et al., 2011; Zhang et al., 2003).
Although it is conceivable that these geographic differences reflect
different environmental constraints, or ethnic differences in the
nuclear genetic background, it is perhaps more likely that theTable 4
Hazard ratios for mortality by mitochondrial haplogroupa
Haplogroup Model 1, hazard
ratio (95%
confidence interval)
Model 1,
p value
Model 2, hazard
ratio (95%
confidence interval)
Model 2,
p value
H 1.10 (0.89e1.36) 0.380 1.04 (0.82e1.31) 0.748
Non-H Reference Reference
T 1.00 (0.70e1.43) 0.988 1.04 (0.72e1.50) 0.852
Non-T Reference Reference
J 0.92 (0.65e1.30) 0.625 0.95 (0.66e1.36) 0.762
Non-J Reference Reference
U 0.97 (0.72e1.31) 0.841 1.13 (0.83e1.55) 0.425
Non-U Reference Reference
K 0.61 (0.38e0.98) 0.041 0.52 (0.30e0.91) 0.023
Non-K Reference Reference
X 2.05 (1.09e3.86) 0.025 1.91 (0.96e3.83) 0.066
Non-X Reference Reference
W 0.85 (0.42e1.72) 0.652 0.90 (0.42e1.92) 0.790
Non-W Reference Reference
I 0.99 (0.41e2.38) 0.973 0.71 (0.26e1.93) 0.506
Non-I Reference Reference
V 1.28 (0.75e2.19) 0.360 1.22 (0.68e2.19) 0.497
Non-V Reference Reference
Bold text indicates p < 0.05.
a Seven binary variables were created of “in haplogroup H” versus “not in hap-
logroup H” type, and 7 models were run entering each binary variable separately.
Model 1 is unadjusted and model 2 is adjusted for sex, ethnicity, total cholesterol,
body mass index, hypertension, diabetes, and smoking.relatively small size of these study groups led to false-positive
associations because mtDNA haplogroup studies are particularly
sensitive to population stratification. In keeping with this, none of
the previously reported positive findings have been replicated
directly, and it is not clear why a particular haplogroup would be
associated with longevity in one context and not the other. Like-
wise, we were unable to replicate previous findings of a gender-
specific association with aging. If present, such an association
would be difficult to explain mechanistically.
Although we cannot exclude the possibility that a larger study
cohort would reveal an association between mtDNA and longevity
and/or healthy aging phenotypes, our findings of a lack of an
association with 2 sensitive and reliable measures of frailty and no
direct evidence of an effect on survival suggest that any contribu-
tion from mtDNA would be modest at best. Our results, therefore,
turn the spotlight away frommtDNA back to the nuclear genome, in
the search for genes predisposing to longevity and healthy aging.Disclosure statement
The authors report no conflicts of interest.
The data contained in the manuscript being submitted have not
been previously published, have not been submitted elsewhere,
and will not be submitted elsewhere while under consideration at
Neurobiology of Aging. All authors have reviewed the contents of the
manuscript being submitted, approved of its contents, and vali-
dated the accuracy of the data.
Ethical approval for the study is in place.Acknowledgements
This work was supported by the Medical Research Council and
the Biotechnology and Biological Sciences Research Council
(G0500997 and G0601333) and The Wellcome Trust (084980/Z/08/
Z, 096919Z/11/Z). P.F.C. is an Honorary Consultant Neurologist at
Newcastle upon Tyne Foundation Hospitals National Health
Service (NHS) Trust, a Wellcome Trust Senior Fellow in Clinical
Science, and a UK National Institute for Health Research (NIHR)
Senior Investigator. This work was also supported by NIHR
J. Collerton et al. / Neurobiology of Aging 34 (2013) 2889.e1e2889.e42889.e4Newcastle Biomedical Research Centre based at Newcastle upon
Tyne Hospitals NHS Foundation Trust and Newcastle University.
The views expressed are those of the author(s) and not necessarily
those of the NHS, the NIHR, or the Department of Health. The
funders had no role in the study design; in the collection, analysis,
and interpretation of data; in the writing of the paper; and in the
decision to submit the paper for publication. Thanks are especially
because of the 85-year olds of Newcastle and North Tyneside for
the generous donation of their time and personal information to
make the study possible. In addition, the authors thank the
research nurses, biomarker technicians, data manager, project
secretary, and NHS North of Tyne (Newcastle Primary Care Trust)
and local general practices.
References
Beekman, M., Blanche, H., Perola, M., Hervonen, A., Bezrukov, V., Sikora, E., et al.,
2013. Genome-wide linkage analysis for human longevity: genetics of Healthy
Aging Study. Aging Cell 12, 184e193.
Benn, M., Schwartz, M., Nordestgaard, B.G., Tybjaerg-Hansen, A., 2008. Mitochon-
drial haplogroups: ischemic cardiovascular disease, other diseases, mortality,
and longevity in the general population. Circulation 117, 2492e2501.
Chinnery, P.F., Mowbray, C., Patel, S.K., Elson, J.L., Sampson, M., Hitman, G.A.,
McCarthy,M.I., Hattersley, A.T.,Walker, M., 2007. Mitochondrial DNA haplogroups
and type 2 diabetes: a study of 897 cases and 1010 controls. J. Med. Genet. 44, e80.
Collerton, J., Davies, K., Jagger, C., Kingston, A., Bond, J., Eccles, M.P., et al., 2009.
Health and disease in 85 year olds: baseline findings from the Newcastle 85þ
cohort study. BMJ 339, b4904.
Collerton, J., Martin-Ruiz, C., Davies, K., Hilkens, C.M., Isaacs, J., Kolenda, C., et al.,
2012. Frailty and the role of inflammation, immunosenescence and cellular
ageing in the very old: cross-sectional findings from the Newcastle 85þ study.
Mech. Ageing Dev. 133, 456e466.
Courtenay, M.D., Gilbert, J.R., Jiang, L., Cummings, A.C., Gallins, P.J., Caywood, L.,
et al., 2012. Mitochondrial haplogroup X is associated with successful aging in
the Amish. Hum. Genet. 131, 201e208.
Dato, S., Passarino, G., Rose, G., Altomare, K., Bellizzi, D., Mari, V., et al., 2004.
Association of the mitochondrial DNA haplogroup J with longevity is population
specific. Eur. J. Hum. Genet. 12, 1080e1082.
De Benedictis, G., Rose, G., Carrieri, G., De Luca, M., Falcone, E., Passarino, G., et al.,
1999. Mitochondrial DNA inherited variants are associated with successful
aging and longevity in humans. Faseb J. 13, 1532e1536.
Dominguez-Garrido, E., Martinez-Redondo, D., Martin-Ruiz, C., Gomez-Duran, A.,
Ruiz-Pesini, E., Madero, P., et al., 2009. Association of mitochondrial haplogroup
J and mtDNA oxidative damage in two different North Spain elderly pop-
ulations. Biogerontology 10, 435e442.Elliott, H.R., Samuels, D.C., Eden, J.A., Relton, C.L., Chinnery, P.F., 2008. Pathogenic
mitochondrial DNA mutations are common in the general population. Am. J.
Hum. Genet. 83, 254e260.
Feng, J., Zhang, J., Liu, M., Wan, G., Qi, K., Zheng, C., et al., 2011. Association of mtDNA
haplogroup F with healthy longevity in the female Chuang population, China.
Exp. Gerontol. 46, 987e993.
Finnila, S., Hassinen, I.E., Ala-Kokko, L., Majamaa, K., 2000. Phylogenetic network of
the mtDNA haplogroup U in Northern Finland based on sequence analysis of the
complete coding region by conformation-sensitive gel electrophoresis. Am. J.
Hum. Genet. 66, 1017e1026.
Fried, L.P., Xue, Q.L., Cappola, A.R., Ferrucci, L., Chaves, P., Varadhan, R., et al., 2009.
Nonlinear multisystem physiological dysregulation associated with frailty in
older women: implications for etiology and treatment. J. Gerontol. A Biol. Sci.
Med. Sci. 64, 1049e1057.
Ivanova, R., Lepage, V., Charron, D., Schachter, F., 1998. Mitochondrial genotype
associated with French Caucasian centenarians. Gerontology 44, 349.
Kirkwood, T.B., Cordell, H.J., Finch, C.E., 2011. Speed-bumps ahead for the genetics of
later-life diseases. Trends Genet. 27, 387e388.
Martin-Ruiz, C., Jagger, C., Kingston, A., Collerton, J., Catt, M., Davies, K., et al., 2011.
Assessment of a large panel of candidate biomarkers of ageing in the Newcastle
85þ study. Mech. Ageing Dev. 132, 496e502.
Niemi, A.K., Hervonen, A., Hurme, M., Karhunen, P.J., Jylha, M., Majamaa, K., 2003.
Mitochondrial DNA polymorphisms associated with longevity in a Finnish
population. Hum. Genet. 112, 29e33.
Niemi, A.K., Moilanen, J.S., Tanaka, M., Hervonen, A., Hurme, M., Lehtimaki, T., et al.,
2005. A combination of three common inherited mitochondrial DNA poly-
morphisms promotes longevity in Finnish and Japanese subjects. Eur. J. Hum.
Genet. 13, 166e170.
Rockwood, K., Mitnitski, A., 2007. Frailty in relation to the accumulation of deficits.
J. Gerontol. A Biol. Sci. Med. Sci. 62, 722e727.
Ross, O.A., McCormack, R., Curran, M.D., Duguid, R.A., Barnett, Y.A., Rea, I.M., et al.,
2001. Mitochondrial DNA polymorphism: its role in longevity of the Irish
population. Exp. Gerontol. 36, 1161e1178.
Schon, E.A., DiMauro, S., Hirano, M., 2012. Human mitochondrial DNA: roles of
inherited and somatic mutations. Nat. Rev. Genet. 13, 878e890.
Tanaka, M., Gong, J., Zhang, J., Yamada, Y., Borgeld, H., Yagi, K., 2000. Mitochondrial
genotype associated with longevity and its inhibitory effect on mutagenesis.
Mech. Ageing Dev. 116, 65e76.
Tanaka, M., Gong, J.-S., Zhang, J., Yoneda, M., Yagi, K., 1998. Mitochondrial genotype
associated with longevity. Lancet 351, 185e186.
Torroni, A., Huoponen, K., Francalacci, P., Petrozzi, M., Morelli, L., Scozzari, R., et al.,
1996. Classification of European mtDNAs from an analysis of three European
populations. Genetics 144, 1835e1850.
Yang, X., Wang, X., Yao, H., Deng, J., Jiang, Q., Guo, Y., et al., 2012. Mitochondrial DNA
polymorphisms are associated with the longevity in the Guangxi Bama pop-
ulation of China. Mol. Biol. Rep. 39, 9123e9131.
Zhang, J., Asin-Cayuela, J., Fish, J., Michikawa, Y., Bonafe, M., Olivieri, F., et al., 2003.
Strikingly higher frequency in centenarians and twins of mtDNA mutation
causing remodeling of replication origin in leukocytes. Proc. Natl. Acad. Sci.
U.S.A. 100, 1116e1121.
